Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry
- 630 Downloads
BReast CAncer genes 1 and 2 (BRCA1 and BRCA2) mutation carriers diagnosed with breast cancer are at increased risk of developing a second primary breast cancer. Data from high-risk clinics may be subject to different biases which can cause both over and underestimation of this risk. Using data from a large multi-institutional family registry we estimated the 10-year cumulative risk of second primary breast cancer including more complete testing information on family members. We prospectively followed 800 women diagnosed with breast cancer from the Breast Cancer Family Registry (BCFR) who were carriers of a BRCA1 or BRCA2 pathogenic mutation or a variant of unknown clinical significance. In order to limit survival and ascertainment bias, cases were limited to those diagnosed with a first primary breast cancer from 1994 to 2001 and enrolled in the BCFR within 3 years after their cancer diagnosis. We excluded women enrolled after being diagnosed with a second breast cancer. We calculated 10-year incidence of second primary breast cancers. The 10-year incidence of a second primary breast cancer was highest in BRCA1 mutation carriers (17 %; 95 % CI 11–25 %), with even higher estimates in those first diagnosed under the age of 40 (21 %; 95 % CI 13–34 %). Lower rates were found in BRCA2 mutation carriers (7 %; 95 % CI 3–15 %) and women with a variant of unknown clinical significance (6 %; 95 % CI 4–9 %). Whereas the cumulative 10-year incidence of second primary breast cancer is high in BRCA1 mutation carriers, the estimates in BRCA2 mutation carriers and women with variants of unknown clinical significance are similar to those reported in women with sporadic breast cancer.
KeywordsBreast cancer BRCA Second primary
This work was supported by grant UM1 CA164920 from the USA National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR.
Conflict of interest
Dr. Chung has stock ownership and consulting role in Bioreference Laboratories.
- 7.Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD002748.pub3
- 9.Hamahata A, Kubo K, Takei H et al (2015) Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study. Breast Cancer 22(3):287–291Google Scholar
- 11.John EM, Hopper JL, Beck JC, Breast Cancer Family Registry et al (2006) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6(4):R375–R389CrossRefGoogle Scholar
- 15.Reding KW, Bernstein JL, Langholz BM, WECARE Collaborative Study Group et al (2010) Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 123(2):491–498CrossRefPubMedCentralPubMedGoogle Scholar